journal article·2021-02-12

Star-Shaped Polylactide Dipyridamole Conjugated to 5-Fluorouracil and 4-Piperidinopiperidine Nanocarriers for Bioimaging and Dual Drug Delivery in Cancer Cells

Dhanya Moorkoth, Kesavan Madhavan Nampoothiri, Selvaraj Nagarajan, Aswathy Ravindran Girija, Sivakumar Balasubramaniyan, D. Sakthi Kumar

ACS Applied Polymer Materials· Volume 3· Issue 2
Publisher page

Abstract

Star-shaped polylactide (SSPLA) nanoparticles (NPs) with dipyridamole (DIP) core conjugated with 5-fluorouracil (5FU) and 4-piperidinopiperidine (4PIP) were designed and synthesized to achieve apoptosis by synergistic dose-dependent delivery than using free drugs. In our current investigation, DIP was employed as the initiator in ring-opening polymerization reaction to make SSPLADIP. We then described the synthesis of tailor-made, self-assembled, carboxyl group-substituted fluorescent SSPLADIP conjugated with a secondary amine group of 5FU anticancer drug to form a dual prodrug complex (SSPLADIP5FU). To compare the efficacy of this combination, another anticancer drug 4PIP was also covalently conjugated with a hydroxyl-end terminal by nucleophilic substitution on SSPLADIP to form SSPLADIP4PIP. 4PIP inhibits the topoisomerase enzyme in DNA replication. Synthesized star-shaped drug constructs were characterized by atomic force microscopy, scanning electron microscopy, NMR, fluorescence spectroscopy, gel permeation chromatography, and MALDI-TOF. This is the first report on these drug combinations (DIP–5FU and DIP–4PIP) fabricated on the polylactic acid biopolymer to form NPs of size <150 nm with excellent encapsulation and loading efficiency with time-dependent release in acidic pH (5.4). The release patterns of NPs were accordant with zero-order and Korsmeyer–Peppas models. The glial (G1), pancreatic (MIAPaCa2), colon (DLD1) cancer cells and normal fibroblast cell line (L929 cells) were used to study the NP uptake in lysosomes and nucleus after 48 h by confocal microscopy. The cytotoxicity of SSPLADIP5FUNPs showed an IC50 of 20 μg/mL in colon cancer cells and remained nontoxic to L929 cells even at 1000 μg/mL. To mimic the colonic environment, we placed free DIP in a simulated colonic fluid with our SSPLADIP5FU NPs. It was observed that our NPs were stable without binding with constituents in the colonic fluid, whereas free DIP bounded with Ca2+, protein, and phosphatidylcholine, resulting in quenching of its fluorescence. Apoptosis by tunability ratios of dual drugs was confirmed by fluorescence activated cell sorting and fluorescence resonance energy transfer assay in flow cytometry.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Microbial Processes and Technology Division, CSIR-NIIST, Trivandrum 695019, Kerala, India

Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India

Department of Chemical Engineering, National Cheng Kung University, Tainan 701, Taiwan

Material sciences Division, CSIR-National Institute for Interdisciplinary Science and Technology (NIIST), Trivandrum 695 019, Kerala, India

Future Industries Institute, University of South Australia, Mawson Lakes Campus, Adelaide 5095, South Australia, Australia

Bio Nano Electronics Research Center, Graduate School of Interdisciplinary New Science, Toyo University, 2100 Kujirai, Kawagoe 3508585, Saitama, Japan

Funding

Council of Scientific and Industrial Research

References (70)

Show source-provided references
1. 10.1039/c6nr00450d10.1039/c6nr00450d ↗
2. 10.1016/j.jconrel.2005.09.01110.1016/j.jconrel.2005.09.011 ↗
3. 10.1021/acs.biomac.9b0102010.1021/acs.biomac.9b01020 ↗
4. 10.1186/1556-276x-8-42010.1186/1556-276x-8-420 ↗
5. 10.1016/j.progpolymsci.2018.10.00410.1016/j.progpolymsci.2018.10.004 ↗
6. 10.1039/b819316a10.1039/b819316a ↗
7. 10.1016/j.progpolymsci.2013.11.00110.1016/j.progpolymsci.2013.11.001 ↗
8. 10.1016/s0169-409x(97)00048-310.1016/s0169-409x(97)00048-3 ↗
9. 10.1039/c2cs15344k10.1039/c2cs15344k ↗
10. 10.1016/j.biortech.2010.05.09210.1016/j.biortech.2010.05.092 ↗
11. 10.1016/j.procbio.2005.09.01310.1016/j.procbio.2005.09.013 ↗
12. 10.1136/gutjnl-2015-31091210.1136/gutjnl-2015-310912 ↗
13. 10.3322/caac.2149210.3322/caac.21492 ↗
14. 10.1002/ijc.2536910.1002/ijc.25369 ↗
15. 10.1016/s0140-6736(00)02034-110.1016/s0140-6736(00)02034-1 ↗
16. 10.1200/jco.2000.18.1.13610.1200/jco.2000.18.1.136 ↗
17. 10.1111/j.1365-2125.2010.03892.x10.1111/j.1365-2125.2010.03892.x ↗
18. 10.1038/nrc359910.1038/nrc3599 ↗
19. Marinaro W. A. · 2007 · 98910.1007/978-0-387-49785-3_27 ↗
20. 10.1021/acs.chemmater.5b0428110.1021/acs.chemmater.5b04281 ↗
21. 10.1021/ja808467510.1021/ja8084675 ↗
22. 10.1021/bc900356g10.1021/bc900356g ↗
23. 10.1002/anie.20080049110.1002/anie.200800491 ↗
24. 10.1021/ma202581d10.1021/ma202581d ↗
25. 10.3897/pharmacia.66.e3773910.3897/pharmacia.66.e37739 ↗
26. 10.1073/pnas.060175510310.1073/pnas.0601755103 ↗
27. Frei E. · Clin. Cancer Res. · 1998 · 4 · 2027
28. 10.1126/scitranslmed.300587210.1126/scitranslmed.3005872 ↗
29. 10.1126/science.221849410.1126/science.2218494 ↗
30. 10.1039/c8md00565f10.1039/c8md00565f ↗
31. 10.1016/0014-4827(63)90243-x10.1016/0014-4827(63)90243-x ↗
32. 10.1021/am509022610.1021/am5090226 ↗
33. 10.1038/s41419-020-2675-x10.1038/s41419-020-2675-x ↗
34. 10.1038/s41598-019-53276-110.1038/s41598-019-53276-1 ↗
35. 10.3748/wjg.v23.i20.363210.3748/wjg.v23.i20.3632 ↗
36. 10.1111/j.1349-7006.1989.tb02339.x10.1111/j.1349-7006.1989.tb02339.x ↗
37. 10.1016/0006-2952(89)90148-210.1016/0006-2952(89)90148-2 ↗
38. 10.1016/0163-7258(89)90084-310.1016/0163-7258(89)90084-3 ↗
39. 10.1038/nrc107410.1038/nrc1074 ↗
40. 10.1200/jco.1995.13.5.120110.1200/jco.1995.13.5.1201 ↗
41. 10.1016/0006-2952(89)90626-610.1016/0006-2952(89)90626-6 ↗
42. Grem J. L. · Cancer Res. · 1985 · 45 · 2967
43. 10.1021/nn900002m10.1021/nn900002m ↗
44. 10.1016/j.cell.2012.03.03110.1016/j.cell.2012.03.031 ↗
45. 10.1021/jm060237r10.1021/jm060237r ↗
46. 10.1016/j.cbi.2005.10.03310.1016/j.cbi.2005.10.033 ↗
47. 10.1016/s0304-3835(98)00029-910.1016/s0304-3835(98)00029-9 ↗
48. 10.1039/c4tb00272e10.1039/c4tb00272e ↗
49. 10.1021/bm800292z10.1021/bm800292z ↗
50. 10.1016/j.polymertesting.2011.12.00510.1016/j.polymertesting.2011.12.005 ↗
51. Vishnukant, B.; Purohit, P.; Paparao, K. Process for the Preparation of Irinotecan Hydrochloride Trihydrate. U.S. Patent 20,080,182,990 A1, 2008.
52. 10.1007/s12010-014-1172-z10.1007/s12010-014-1172-z ↗
53. 10.1590/s1984-8250201300010001310.1590/s1984-82502013000100013 ↗
54. 10.1097/00007691-200502000-0000610.1097/00007691-200502000-00006 ↗
55. 10.1016/j.ijpharm.2003.09.03610.1016/j.ijpharm.2003.09.036 ↗
56. 10.2147/IJN.S4988210.2147/IJN.S49882 ↗
57. 10.1002/jbm.a.3320310.1002/jbm.a.33203 ↗
58. 10.1186/1471-2407-8-10310.1186/1471-2407-8-103 ↗
59. 10.1158/0008-5472.can-09-194710.1158/0008-5472.can-09-1947 ↗
60. 10.1038/nmat299910.1038/nmat2999 ↗
61. 10.1186/1475-2867-13-8910.1186/1475-2867-13-89 ↗
62. 10.1039/b816603j10.1039/b816603j ↗
63. 10.1021/acsapm.9b0041310.1021/acsapm.9b00413 ↗
64. 10.1002/jcp.2099410.1002/jcp.20994 ↗
65. 10.1158/1078-0432.ccr-1134-0310.1158/1078-0432.ccr-1134-03 ↗
66. 10.1038/sj.onc.121100810.1038/sj.onc.1211008 ↗
67. 10.3748/wjg.v20.i42.1568210.3748/wjg.v20.i42.15682 ↗
68. 10.1124/mol.104.00994410.1124/mol.104.009944 ↗
69. Manos E. · Cancer Res. · 2001 · 61 · 433
70. 10.1371/journal.pone.010701010.1371/journal.pone.0107010 ↗